Rivive is a drug owned by Harm Reduction Therapeutics Inc. It is protected by 2 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 11, 2032. Details of Rivive's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11020343 | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(7 years from now) | Active |
| US11806428 | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rivive's patents.
Latest Legal Activities on Rivive's Patents
Given below is the list of recent legal activities going on the following patents of Rivive.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 07 Nov, 2023 | US11806428 |
| Patent eGrant Notification | 07 Nov, 2023 | US11806428 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11806428 |
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11806428 |
| Email Notification Critical | 07 Nov, 2023 | US11806428 |
| Recordation of Patent Grant Mailed Critical | 07 Nov, 2023 | US11806428 |
| Email Notification Critical | 19 Oct, 2023 | US11806428 |
| Issue Notification Mailed Critical | 18 Oct, 2023 | US11806428 |
| Application Is Considered Ready for Issue Critical | 04 Oct, 2023 | US11806428 |
| Dispatch to FDC | 04 Oct, 2023 | US11806428 |
US patents provide insights into the exclusivity only within the United States, but Rivive is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rivive's family patents as well as insights into ongoing legal events on those patents.
Rivive's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rivive's generic launch date based on the expiry of its last outstanding patent is estimated to be May 11, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rivive Generic API suppliers:
Naloxone Hydrochloride is the generic name for the brand Rivive. 29 different companies have already filed for the generic of Rivive, with Igi Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rivive's generic
Alternative Brands for Rivive
Rivive which is used for reversing opioid overdose., has several other brand drugs using the same active ingredient (Naloxone Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Bdsi |
| |||
| Emergent |
| |||
| Hikma |
| |||
| Indivior |
| |||
| Kaleo Inc |
| |||
| Orexo Us Inc |
| |||
| Purdue Pharma Lp |
| |||
| Zmi Pharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Naloxone Hydrochloride, Rivive's active ingredient. Check the complete list of approved generic manufacturers for Rivive
About Rivive
Rivive is a drug owned by Harm Reduction Therapeutics Inc. It is used for reversing opioid overdose. Rivive uses Naloxone Hydrochloride as an active ingredient. Rivive was launched by Harm Reduction Therp in 2023.
Approval Date:
Rivive was approved by FDA for market use on 28 July, 2023.
Active Ingredient:
Rivive uses Naloxone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Naloxone Hydrochloride ingredient
Treatment:
Rivive is used for reversing opioid overdose.
Dosage:
Rivive is available in spray, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3MG/SPRAY | SPRAY, METERED | Over the counter | NASAL |